A Study to Evaluate the Field Efficacy of Ivermectin, Fenbendazole And

Total Page:16

File Type:pdf, Size:1020Kb

A Study to Evaluate the Field Efficacy of Ivermectin, Fenbendazole And Article — Artikel A study to evaluate the field efficacy of ivermectin, fenbendazole and pyrantel pamoate, with preliminary observations on the efficacy of doramectin, as anthelmintics in horses J A Daviesa* and L M J Schwalbachb tance has indicated the need for alterna- ABSTRACT tive or complementary methods of The efficacy of ivermectin, fenbendazole, pyrantel pamoate and doramectin was evaluated parasite control and additional effective under field conditions at 2 sites in the Free State Province of South Africa. The study in- drugs. An example of the more recently volved 25 horses at each site, divided into 5 groups of equal size. Ivermectin, fenbendazole developed drugs is doramectin, an and pyrantel pamoate were administered orally at doses of 0.2, 10 and 19 mg/kg respec- avermectin currently registered for use in tively. Doramectin was administered by intramuscular injection at a dose of 0.2 mg/kg. sheep, cattle and swine in South Africa Treatment efficacy was based on the mean faecal egg count reduction 14 days post treat- (Dectomax, Pfizer). Although not regis- ment. At site A a faecal egg count reduction of 100 % was found after treatment with ivermectin, fenbendazole and doramectin. A 96.1 % reduction was found after treatment tered for use in horses, doramectin is cur- with pyrantel pamoate. At site B ivermectin and doramectin produced a 100 % reduction in rently used by many horse owners who faecal egg counts, fenbendazole produced an 80.8 % reduction and pyrantel pamoate a are claiming excellent results and no 94.1 % reduction. Doramectin produced a 100 % reduction in faecal egg counts at both sites, adverse side-effects. despite not being registered for use in horses. In addition, the results indicated reduced The aim of this study was to investigate efficacy of fenbendazole at site B, which suggested benzimidazole resistance. Larval cul- the efficacy of the main groups of anthel- tures showed that cyathostomes accounted for between 86 and 96 % of pre-treatment para- mintics in South Africa, where limited site burdens at both sites. Other helminths identified in the faecal samples were Strongylus studies have been conducted to date, and spp. and Trichostrongylus axei. to assess the efficacy of doramectin as an Key words: anthelmintic, cyathostomes, doramectin, equine, fenbendazole, horse, anthelmintic for horses. ivermectin, pyrantel, resistance. Davies J A, Schwalbach L M J A study to evaluate the field efficacy of ivermectin, MATERIALS AND METHODS fenbendazole and pyrantel pamoate, with preliminary observations on the efficacy of This study involved 50 horses, 25 at each doramectin, as anthelmintics in horses. Journal of the South African Veterinary Association of 2 sites (sites A and B) in the eastern Free 71(3): 144–147 (En.). Equine Veterinary Practice, PO Box 1075, Shelbyville, KY 40066, USA. State Province. The trial was conducted between December and January, when day temperatures averaged 28 °C and there had been no rain for approximately INTRODUCTION to be restricted to the cyathostomes and 4 months. All horses included had not Intestinal parasites are important fac- most commonly involves the benzimi- received anthelmintic treatment for at tors in the aetiology of gastrointestinal dazole anthelmintics, although resistance least 3 months and had at least 100 eggs disease and are also of economic impor- to pyrantel has also been detected2,3,5,7,9,13. per gram (EPG) at the beginning of the tance in horses throughout the world. It is Anthelmintic resistance in cyathostomes trial. The horses were predominantly not yet certain to what extent immunity is of horses has become widely documented Arabians, part-bred Arabians, Appaloosas acquired either with age or exposure16,17,29, over the last 3 decades and has been and Basutho ponies. and as a result, for many years, the control reported in most countries of the world1. Site A: horses were aged from 2 to 22 of equine parasites has depended largely In South Africa only a single study in years. All horses were kept on grass on the administration of anthelmintics, to which benzimidazole resistance was although some received supplementary remove adult parasites and prevent egg reported has been documented34. concentrates. Only 4 of these horses production with a subsequent reduction Cyathostomes commonly produce received regular treatment (every 6 in infective larvae on pastures. 75–100 % of eggs passed in the faeces of months) with ivermectin (Ivomec liquid, Intensive anthelmintic usage appears to naturally infected, adult, grazing horses4. Logos Agvet), the last treatment having select for those nematodes that can In contrast to previously held beliefs, it been administered approximately 6 survive treatment. The reproduction of has now been established that cyatho- months before the study. No other these individuals and the further treat- stomes can be highly pathogenic or even method of parasite control was imple- ment of their progeny with the same type fatal10,24. Their clinical effects range from mented. The pastures were grazed only of anthelmintic progressively selects for poor performance and colic to fatal enter- by horses. resistance26. Resistance in horses appears itis5,18. They are also responsible for the Site B: horses were aged from 3 months potentially fatal larval cyathostomiasis to 33 years. Two horses were stabled at aEquine Veterinary Practice, PO Box 1075, Shelbyville, KY 40066, USA. caused by mass emergence of hypobiotic night, receiving supplementary hay and bUniversity of the Orange Free State, Department of larvae usually seen in spring. These ob- concentrates. Of the others, which were Animal Science, PO Box 339, Bloemfontein, 9300 South Africa. servations illustrate the need for effective kept on grass, some also received supple- *Author for correspondence. cyathostome control. mentary hay and/or concentrates. The Received: December 1999. Accepted: June 2000. The development of anthelmintic resis- horses received anthelmintics at fixed 144 0038-2809 Tydskr.S.Afr.vet.Ver. (2000) 71(3): 144–147 Table 1: Mean faecal egg counts (± standard deviations) and reductions for each group at sites A and B. Site A Site B Group Arithmetic mean Arithmetic mean Mean Arithmetic mean Arithmetic mean Mean (Day 0) (Day 14) % reduction (Day 0) (Day 14) % reduction IVM 2210 ± 1166 0** 100 1650 ± 823 0** 100 DRM 2220 ± 1324 0** 100 1580 ± 974 0** 100 FBZ 2200 ± 1226 0** 100 1510 ± 917 290* ± 139 80.8 PYR 2290 ± 1088 90** ± 49 96.1 1530 ± 884 90** ± 58 94.1 Control 2140 ± 1466 1670 ± 1105 22 1720 ± 820 1400 ± 683 18.6 *P < 0.05; **P < 0.01. 3-monthly intervals. The drugs used Statistical methods 0.01) were found between mean faecal included fenbendazole (Panacur liquid, The effects of the different anthel- egg counts on day 0 and day 14 for all Hoechst), ivermectin (Ivomec liquid, mintics were estimated using the faecal treated groups except the fenbendazole- Logos Agvet) and doramectin (Dectomax egg count reduction test. Arithmetic treated group at site B, which showed a liquid, Pfizer). No particular rotation was means of the day 0 and day 14 egg counts less significant reduction (P < 0.05). At site used. Fenbendazole (Panacur liquid, were calculated to determine the mean A, significant differences (P < 0.01) were Hoechst) was the most recent treatment percentage reductions within each found between the mean EPGs of the con- administered, having been given approx- group. Two-way analysis of variance was trol and all the treatment groups on day imately 3 months before the study. No performed to evaluate the effect of day of 14. At site B the mean EPG of the control other management practices were em- sampling and treatment administered on and the treated groups were also signifi- ployed as methods of parasite control. mean faecal egg counts. Multiple compar- cantly different on day 14 (P < 0.01, for Mixed grazing with cattle and sheep isons were then made using the ivermectin, doramectin and pyrantel occurred periodically. Tukey-HSD interval. Analysis was carried pamoate and P<0.05, for the fenben- out on logarithmic transformed data dazole-treated group). It was not appro- Design of study (log10 faecal egg count + 1), as the sample priate to pool the results from the 2 sites Faecal samples were collected from all size was small and the data could not be for statistical analysis, as it was apparent horses and analysed the same day using a assumed to be normally distributed. that there were between-site variations in modified McMaster technique with a sen- the faecal egg count reductions in the sitivity of 50 EPG. Horses were allocated RESULTS fenbendazole-treated groups (P < 0.01). to 1 of 5 equal-sized groups according to the EPG and, where possible, sex and age. Faecal egg count reductions Larval identification Anthelmintic treatment was carried out The results of the day 0 and day 14 mean The pre-treatment larval cultures the following day. On Day 14 post treat- EPG values from both sites are presented yielded 86 % cyathostomes and 14 % ment, faecal samples were again collected in Table 1, together with the mean faecal Strongylus spp. at site A and 96 % cyatho- from each horse and faecal egg counts egg count reductions. Ivermectin and stomes, 3 % Strongylus spp. and 1 % Tri- performed. Post-treatment samples were doramectin produced 100 % reductions at chostrongylus axei at site B. processed blind so that there was no both sites. Pyrantel pamoate showed Third-stage larvae from the pyrantel knowledge of the treatment group. Be- 96.1 % efficacy at site A and 94.1 % at site pamoate-treated group at site A were fore and after treatment, bulk faecal sam- B. Fenbendazole was 100 % effective at 98 % cyathostomes and 2 % Strongylus ples from each site were kept at room site A and 80.8 % effective at site B. spp. From site B, 98 % were cyathostomes, temperature (approx.
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Parasiticides: Fenbendazole, Ivermectin, Moxidectin Livestock
    Parasiticides: Fenbendazole, Ivermectin, Moxidectin Livestock 1 Identification of Petitioned Substance* 2 3 Chemical Names: 48 Ivermectin: Heart Guard, Sklice, Stomectol, 4 Moxidectin:(1'R,2R,4Z,4'S,5S,6S,8'R,10'E,13'R,14'E 49 Ivomec, Mectizan, Ivexterm, Scabo 6 5 ,16'E,20'R,21'R,24'S)-21',24'-Dihydroxy-4 50 Thiabendazole: Mintezol, Tresaderm, Arbotect 6 (methoxyimino)-5,11',13',22'-tetramethyl-6-[(2E)- 51 Albendazole: Albenza 7 4-methyl-2-penten-2-yl]-3,4,5,6-tetrahydro-2'H- 52 Levamisole: Ergamisol 8 spiro[pyran-2,6'-[3,7,1 9]trioxatetracyclo 53 Morantel tartrate: Rumatel 9 [15.6.1.14,8.020,24] pentacosa[10,14,16,22] tetraen]- 54 Pyrantel: Banminth, Antiminth, Cobantril 10 2'-one; (2aE, 4E,5’R,6R,6’S,8E,11R,13S,- 55 Doramectin: Dectomax 11 15S,17aR,20R,20aR,20bS)-6’-[(E)-1,2-Dimethyl-1- 56 Eprinomectin: Ivomec, Longrange 12 butenyl]-5’,6,6’,7,10,11,14,15,17a,20,20a,20b- 57 Piperazine: Wazine, Pig Wormer 13 dodecahydro-20,20b-dihydroxy-5’6,8,19-tetra- 58 14 methylspiro[11,15-methano-2H,13H,17H- CAS Numbers: 113507-06-5; 15 furo[4,3,2-pq][2,6]benzodioxacylooctadecin-13,2’- Moxidectin: 16 [2H]pyrano]-4’,17(3’H)-dione,4’-(E)-(O- Fenbendazole: 43210-67-9; 70288-86-7 17 methyloxime) Ivermectin: 59 Thiabendazole: 148-79-8 18 Fenbendazole: methyl N-(6-phenylsulfanyl-1H- 60 Albendazole: 54965-21-8 19 benzimidazol-2-yl) carbamate 61 Levamisole: 14769-72-4 20 Ivermectin: 22,23-dihydroavermectin B1a +22,23- 21 dihydroavermectin B1b 62 Morantel tartrate: 26155-31-7 63 Pyrantel: 22204-24-6 22 Thiabendazole: 4-(1H-1,3-benzodiazol-2-yl)-1,3- 23 thiazole
    [Show full text]
  • Sheet1 Page 1 a Abamectin Acetazolamide Sodium Adenosine-5-Monophosphate Aklomide Albendazole Alfaxalone Aloe Vera Alphadolone A
    Sheet1 A Abamectin Acetazolamide sodium Adenosine-5-monophosphate Aklomide Albendazole Alfaxalone Aloe vera Alphadolone Acetate Alpha-galactosidase Altrenogest Amikacin and its salts Aminopentamide Aminopyridine Amitraz Amoxicillin Amphomycin Amphotericin B Ampicillin Amprolium Anethole Apramycin Asiaticoside Atipamezole Avoparcin Azaperone B Bambermycin Bemegride Benazepril Benzathine cloxacillin Benzoyl Peroxide Benzydamine Bephenium Bephenium Hydroxynaphthoate Betamethasone Boldenone undecylenate Boswellin Bromelain Bromhexine 2-Bromo-2-nitropan-1, 3 diol Bunamidine Buquinolate Butamisole Butonate Butorphanol Page 1 Sheet1 C Calcium glucoheptonate (calcium glucoheptogluconate) Calcium levulinate Cambendazole Caprylic/Capric Acid Monoesters Carbadox Carbomycin Carfentanil Carnidazole Carnitine Carprofen Cefadroxil Ceftiofur sodium Centella asiatica Cephaloridine Cephapirin Chlorine dioxide Chlormadinone acetate Chlorophene Chlorothiazide Chlorpromazine HCl Choline Salicylate Chondroitin sulfate Clazuril Clenbuterol Clindamycin Clomipramine Clopidol Cloprostenol Clotrimazole Cloxacillin Colistin sulfate Copper calcium edetate Copper glycinate Coumaphos Cromolyn sodium Crystalline Hydroxycobalamin Cyclizine Cyclosporin A Cyprenorphine HCl Cythioate D Decoquinate Demeclocycline (Demethylchlortetracycline) Page 2 Sheet1 Deslorelin Desoxycorticosterone Pivalate Detomidine Diaveridine Dichlorvos Diclazuril Dicloxacillin Didecyl dimethyl ammonium chloride Diethanolamine Diethylcarbamazine Dihydrochlorothiazide Diidohydroxyquin Dimethylglycine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0143956A1 Cady Et Al
    US 2013.0143956A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0143956A1 Cady et al. (43) Pub. Date: Jun. 6, 2013 (54) LONG-ACTING INJECTABLE MOXIDECTIN (22) Filed: Nov.30, 2012 FORMULATIONS AND NOVEL MOXDECTIN CRYSTAL FORMS Related U.S. Application Data (71) Applicants: Susan Mancini Cady, Yardley, PA (US); (60) Provisional application No. 61/566,336, filed on Dec. Baoqing Ma, Kendall Park, NJ (US); 2, 2011. Robert Clark Chapman, Downingtown, Publication Classification PA (US); Chunhua Yang, Edison, NJ (US); Uday Jain, Plainsboro, NJ (US) (51) Int. Cl. A6IK3I/365 (2006.01) (72) Inventors: Susan Mancini Cady, Yardley, PA (US); (52) U.S. Cl. Baoqing Ma, Kendall Park, NJ (US); CPC .................................... A61 K3I/365 (2013.01) Robert Clark Chapman, Downingtown, USPC ............................ 514/450; 549/264; 264/145 PA (US); Chunhua Yang, Edison, NJ (US); Uday Jain, Plainsboro, NJ (US) (57) ABSTRACT This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric (73) Assignee: Merial Limited, Duluth, GA (US) implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and pre (21) Appl. No.: 13/690,185 Venting of endo- and ectoparasite infections in animals. Patent Application Publication Jun. 6, 2013 Sheet 1 of 33 US 2013/0143956 A1 FIG. I. Six: Restivati Masaaaaaaaaaaaaaaaaaaaaaaaaaaa estivate 83 3 R33 Patent Application Publication Jun. 6, 2013 Sheet 2 of 33 US 2013/0143956 A1 FIG 2A Conventional DSC of Moxidectin lot SO9060: ... -- ; : f; : : ^ ‘s 1119°C f ---. f - “r-. f a. -: ; Agree 18649°Cs f 2) skirt" ----.
    [Show full text]
  • Alpaca and Llama Parasite Treatment
    Alpaca and Llama Parasite Treatment Albendazole (Valbazen) 10mg/kg Do not recommend in pregnancy or for young crias! Much better for killing tapeworms than Fenbendazole. Give orally - 6cc/100 pounds of body weight. Give one dose once per day for three days in a row (max). May need to repeat in two weeks depending on parasite load. May also have an ovacidal effect – meaning that it kills eggs and thus prevents pasture contamination – therefore it is good for isolation pens. Doramectin (Dectomax) 1cc/50 pounds of body weight every 8 weeks. Or give 1cc/70 pounds of body weight every 6 weeks. Give SubQ. (Recommend 20 gauge needle) Primarily for Meningeal Worm prevention. May kill some strongyles. Probably ineffective against most Nematodirus and Trichuris. Ivermectin (Ivomec) 1cc/70 pounds of body weight for Meningeal Worm prevention. Note that efficacy lasts for no more than 4 weeks max! Excellent for mange treatment: Dose at 1cc/50 pounds for mange – 3 days in row, and then repeat one dose in one week. Do not give mange treatment to pregnant females within first 60 days of pregnancy! Give SubQ. (Recommend 20 gauge needle) Probably ineffective in llamas and alpacas for Trichuris, Nematodirus, Moniezia, some strongyles, and liver flukes. You can purchase Ivomec Plus to kill liver flukes. Fenbendazole (Panacur or Safeguard) 20mg/kg or 1cc/10 pounds of body weight Give orally three days in row for Nematodirus. Give orally 5 days in a row and repeat in 2 weeks for Trichuris and Moneizia (tapeworms). This is a very safe drug, even for very young crias and newly pregnant females! Levamisole 8mg/kg Oral drug is safer than the injectible version.
    [Show full text]
  • Evaluation of the Efficacy of Doramectin in the Control Of
    Evaluation of the Efficacy of Doramectin in the Control of Strongyle (Strongylidae, Cyathostominae) Infestation in Horses Prokulewicz, A., Pilarczyk, B.* and Tomza-Marciniak, A. Department of Animal Reproduction Biotechnology and Environmental Hygiene, Faculty of Biotechnology and Animal Husbandry, West Pomeranian University of Technology, Szczecin Doktora Judyma St. 6, 71-466 Szczecin, Poland. *Corresponding author: Dr. hab. Bogumiła Pilarczyk, Department of Animal Reproduction Biotechnology and Environmental Hygiene, West Pomeranian University of Technology, Szczecin. Tel: +48 91 449 67 91. Email: [email protected]. ABSTRACT The aim of the study was to evaluate the efficacy of doramectin (Dectomax) in the control of strongyle (Strongylidae, Cyathostominae) infestations in horses. The research involved 24 horses of various breeds (stallions and mares), aged 1.5 to19 years of age. The prevalence and intensity of infestation were determined based on coproscopic examination using Willis-Schlaf and Mc-Master methods. Drug resistance was determined by fecal egg count reduction test (FECRT). Horses were injected subcutaneously with doramectin at a dose of 0.2 mg/kg bodyweight. Doramectin had an efficacy of 99.6% on day 14 and strongyles reappeared 2 months after doramectin administration. Subcutaneously injected doramectin proved highly effective in the control of strongyle (Strongylidae, Cyathostominae) infestations in horses. Keywords: Horses,equine, Strongylidae, Cyathostominae, Dectomax, Doramectin, drug resistance. INTRODUCTION in horses includes drug under-dosing, alternating admin- Diseases caused by parasites are still among the most com- istration of drugs belonging to the same class of chemical mon illnesses in equine populations despite great advances compounds, parasites coming into frequent contact with the in anti-parasite drug development and use (1-4).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 01 Front.Pdf (2.451Mb)
    Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author. VETERINARY ANTHELMINTICS: THEIR EFFICACY AND EFFECTS ON ABOMASAL PHYSIOLOGY A thesis presented in partial fulfilment of the requirements for the degree of MASTER OF VETERINARY SCIENCE in Veterinary Clinical Pharmacology at Massey University NICHOLAS CHARLES WHELAN March 1998 For Pauline, with all my love iii ABSTRACT PART 1. A Review of the Veterinary Anthelmintic Literature A comprehensive review was undertaken of the pharmacology, efficacy, side effects and toxicity of veterinary anthelmintics used against nematode parasites. Anthelmintics reviewed for use in cattle, sheep, goats, horses, dogs and cats include copper, nicotine, arsenic, tetrachlorethylene, phenothiazine, diethylcarbamazine, piperazine, toluene, cyacethydrazide, bephenium, thenium, organophosphates, and methyridine. The review was limited to cattle for the benzimidazoles, pyrantel, morantel, tetramisole, levamisole, avermectin and milbemycins anthelmintics. Efficacy data is provided in a tabular format which classifies each anthelmintic according to method of administration and dose. PART2 Efficacy of two formulations of moxidectin pour-on and the effects of treatment on serum pepsinogen and gastrin levels and tissue gastrin in cattle Three groups of eight yearling Friesian bulls were used to compare the efficacy of two 5 g/L pour-on formulations of moxidectin applied at 1ml/10kg (500 mcg moxidectin per kg bodyweight) in removing naturally acquired gastrointestinal parasites. At slaughter, 14-16 days after treatment, the burdens of Ostertagia spp. and Trichostrongylus axei were significantly lower in both the treated groups versus the controls (P<0.01 ).
    [Show full text]
  • Feedlot Gastrointestinal Parasite Control and Anthellllintic Treatment Options, a Review
    PEER REVIEWED Feedlot gastrointestinal parasite control and anthellllintic treatment options, a review Matthew D. Edmonds, DVM, PhD; Edward G. Johnson, DVM; Jenifer D. Edmonds, DVM, PhD Johnson Research, LLC, Parma, ID 83660 Corresponding author: Dr. Jenifer Edmonds, Tel.: 208-722-5829, Email address:[email protected] Abstract efficacious anthelmintics for the feedlot industry is well recognized. Typically, when compared to non-treated con­ Anthelmintics are an important tool in the feedlot trols, deworming can be expected to improve dry matter industry. The goal of this review article is to provide intake, feed efficiency, and weight gain. Often an improve­ the veterinary practitioner with a short summary ment in carcass quality is also observed with anthelmintic of the important aspects of internal gastrointestinal treatment. This treatment effect was shown in a single parasite control in the feedlot. A review of economically feedlot trial with over 6000 heavyweight yearling steers.10 significant gastrointestinal nematodes and the bovine In this study, treatment with an injectable avermectin at liver fluke is provided, along with a discussion of treat­ feedlot entry was associated with statistically significant ment options and an anthelmintic efficacy assessment. improvements in average daily gain (ADG), dry matter Important aspects unique to the feedlot environment intake, feed efficiency, and carcass grading when com­ are addressed, including anthelmintic resistance and pared to negative controls. combination anthelmintic therapies. Bovine Nematodes Key words: bovine, feedlot, parasitology, anthelmintic, gastrointestinal nematodes, flukes Important abomasal nematode parasites offeedlot cattle include Ostertagia ostertagi, Haemonchus placei, Resume and Trichostrongylus axei. In terms of relative clinical importance, 0. ostertagi is considered the most impor­ Les anthelminthiques sont des outils importants tant helminth parasite of cattle in the United States.2 pour l'industrie des pares d'engraissement.
    [Show full text]
  • IJP: Drugs and Drug Resistance 10 (2019) 69–83
    IJP: Drugs and Drug Resistance 10 (2019) 69–83 Contents lists available at ScienceDirect IJP: Drugs and Drug Resistance journal homepage: www.elsevier.com/locate/ijpddr Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance T ∗ ∗∗ Roger K. Prichard , Timothy G. Geary Institute of Parasitology, McGill University, Sainte Anne-de-Bellevue, Quebec, Canada, H9X3V9 ARTICLE INFO ABSTRACT Keywords: Macrocyclic lactone (ML) anthelmintics are the most important class of anthelmintics because of our high de- Moxidectin pendence on them for the control of nematode parasites and some ectoparasites in livestock, companion animals Milbemycin and in humans. However, resistance to MLs is of increasing concern. Resistance is commonplace throughout the Ivermectin world in nematode parasites of small ruminants and is of increasing concern in horses, cattle, dogs and other Avermectin animals. It is suspected in Onchocerca volvulus in humans. In most animals, resistance first arose to the aver- Macrocyclic lactone resistance mectins, such as ivermectin (IVM), and subsequently to moxidectin (MOX). Usually when parasite populations Nematode are ML-resistant, MOX is more effective than avermectins. MOX may have higher intrinsic potency against some parasites, especially filarial nematodes, than the avermectins. However, it clearly has a significantly different pharmacokinetic profile. It is highly distributed to lipid tissues, less likely to be removed by ABC efflux trans- porters, is poorly metabolized and has a long half-life. This results in effective concentrations persisting for longer in target hosts. It also has a high safety index. Limited data suggest that anthelmintic resistance may be overcome, at least temporarily, if a high concentration can be maintained at the site of the parasites for a prolonged period of time.
    [Show full text]
  • Comparison of the Environmental Properties of Parasiticides and Harmonisation of the Basis for Environmental Assessment at the EU Level
    Environmental Research of the Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety Project number: 3714 64 410 0 Report number: [entered by the UBA library] Comparison of the environmental properties of parasiticides and harmonisation of the basis for environmental assessment at the EU level by Jörg Römbke, Karen Duis, Philipp Egeler, Daniel Gilberg, Christine Schuh ECT Oekotoxikologie GmbH, Böttgerstr. 2-14, D-65439 Flörsheim Monika Herrchen, Dieter Hennecke Fraunhofer-Institute for Molecular Biology and Applied Ecology, Auf dem Aberg 1, D-57392 Schmallenberg Ludwig E. Hölzle, Brigitte Heilmann-Thudium University of Hohenheim, Livestock Infectiology and Environmental Hygiene, Garbenstr. 30, D-70599 Stuttgart Manuel Wohde, Julia Wagner, Rolf-Alexander Düring Justus Liebig University, Institute for Soil Science and Soil Conservation, Heinrich Buff-Ring 26, D-35392 Gießen On behalf of the German Environment Agency Completion date: May 2018 Comparison of the environmental properties of parasiticides and harmonisation of the basis for environmental assessment at the EU level Abstract Avermectin and milbemycin parasiticides have a high toxicity to non-target organisms, are often per- sistent and may have a potential to bioaccumulate. The present project contributes to filling gaps in the database for a complete environmental risk assessment of these parasiticides. In addition, risk management strategies for parasiticides used in pasture animals were discussed. For ivermectin and selamectin, log POW values of 5.6 and 6.0 were derived, respectively. In studies with zebrafish, biocon- centration factors of 63–111 for ivermectin and 70–71 for doramectin (based on total radio-active residues, normalised to a 5% lipid content) were determined.
    [Show full text]
  • Arzneimittelrückstände in Der Umwelt
    Arzneimittelrückstände in der Umwelt ARZNEIMITTELRÜCKSTÄNDE IN DER UMWELT Christina Hartmann REPORT REP-0573 Wien 2016 Projektleitung Sigrid Scharf AutorInnen Christina Hartmann Mitarbeit Manfred Clara Sigrid Scharf Monika Denner Übersetzung Brigitte Read Lektorat Maria Deweis Satz/Layout Manuela Kaitna Umschlagphoto © gunnar3000 – Fotolia.com Weitere Informationen zu Umweltbundesamt-Publikationen unter: http://www.umweltbundesamt.at/ Impressum Medieninhaber und Herausgeber: Umweltbundesamt GmbH Spittelauer Lände 5, 1090 Wien/Österreich Eigenvervielfältigung Das Umweltbundesamt druckt seine Publikationen auf klimafreundlichem Papier. © Umweltbundesamt GmbH, Wien, 2016 Alle Rechte vorbehalten ISBN 978-3-99004-386-8 Arzneimittelrückstände in der Umwelt – Inhalt INHALT ZUSAMMENFASSUNG .......................................................................... 7 SUMMARY .............................................................................................. 8 1 EINLEITUNG ........................................................................................... 9 2 DURCHFÜHRUNG ............................................................................... 10 3 HUMANARZNEIMITTEL ...................................................................... 11 3.1 Begriffsbestimmungen lt. Arzneimittelgesetz (AMG) ...................... 11 3.2 ATC-Klassifizierung ............................................................................ 11 3.3 Pharmakokinetik ................................................................................. 12
    [Show full text]